FY2029 Earnings Estimate for ENTA Issued By HC Wainwright

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, December 24th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings of ($6.62) per share for the year. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Several other equities research analysts have also commented on ENTA. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird decreased their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $6.10 on Wednesday. The company has a market capitalization of $129.28 million, a P/E ratio of -1.11 and a beta of 0.49. Enanta Pharmaceuticals has a 12 month low of $5.70 and a 12 month high of $17.80. The firm’s fifty day simple moving average is $9.52 and its 200-day simple moving average is $11.61.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. During the same quarter last year, the company posted ($1.33) EPS. Enanta Pharmaceuticals’s quarterly revenue was down 22.8% compared to the same quarter last year.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in Enanta Pharmaceuticals by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after buying an additional 1,548 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter worth approximately $35,000. US Bancorp DE lifted its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares in the last quarter. American Century Companies Inc. boosted its stake in Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after purchasing an additional 7,287 shares during the last quarter. Finally, Quest Partners LLC grew its holdings in shares of Enanta Pharmaceuticals by 65.0% during the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after buying an additional 7,535 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.